Daniel R. Thomas

Adelaide, SA, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 78 publications

Untrustworthy sources on Facebook and Instagram in 2020: Concentrated exposure but no attitudinal effects.

Untrustworthy sources on Facebook and Instagram in 2020: Concentrated exposure but no attitudinal effects.

Journal: Science advances
Published: July 29, 2026

Evaluating response criteria in myelodysplastic/myeloproliferative neoplasms: a systematic review and meta-analysis.

Evaluating response criteria in myelodysplastic/myeloproliferative neoplasms: a systematic review and meta-analysis.

Journal: Blood neoplasia
Published: April 22, 2026

CD47 stabilizes ROBO2 to regulate glioblastoma progression by preventing ITCH-mediated ubiquitination.

CD47 stabilizes ROBO2 to regulate glioblastoma progression by preventing ITCH-mediated ubiquitination.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 23, 2026

Mitochondrial DNA mutations are associated with impaired oxidative phosphorylation and enhanced imatinib response in chronic myeloid leukemia.

Mitochondrial DNA mutations are associated with impaired oxidative phosphorylation and enhanced imatinib response in chronic myeloid leukemia.

Journal: HemaSphere
Published: March 18, 2026

A Reliable Method for Thawing Primary AML and CMML Mononuclear Cells to Preserve Viability and Function.

A Reliable Method for Thawing Primary AML and CMML Mononuclear Cells to Preserve Viability and Function.

Journal: Bio-protocol
Published: March 17, 2026

IRF2BP2::JAK2 Defines a Novel Kinase-Activating Fusion in Pediatric T-Cell Acute Lymphoblastic Leukemia.

IRF2BP2::JAK2 Defines a Novel Kinase-Activating Fusion in Pediatric T-Cell Acute Lymphoblastic Leukemia.

Journal: Genes, chromosomes & cancer
Published: October 09, 2025

RAS mutation identifies a poor prognostic molecular subtype of therapy-related myeloid neoplasm.

RAS mutation identifies a poor prognostic molecular subtype of therapy-related myeloid neoplasm.

Journal: Blood advances
Published: March 05, 2025

Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort.

Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort.

Journal: Blood cancer journal
Published: December 27, 2024

How deceptive online networks reached millions in the US 2020 elections.

How deceptive online networks reached millions in the US 2020 elections.

Journal: Nature human behaviour
Published: December 20, 2024

Ultraprecision Therapy for Type 1 vs Type 2 CALR+ MPN by Dual Epitope Targeting that Restores Ruxolitinib Sensitivity.

Ultraprecision Therapy for Type 1 vs Type 2 CALR+ MPN by Dual Epitope Targeting that Restores Ruxolitinib Sensitivity.

Journal: Blood
Published: December 09, 2024

Ultraprecision therapy for type 1 vs type 2 CALR+ MPN by dual epitope targeting that restores ruxolitinib sensitivity.

Ultraprecision therapy for type 1 vs type 2 CALR+ MPN by dual epitope targeting that restores ruxolitinib sensitivity.

Journal: Blood
Published: December 09, 2024

Distinct metabolome and flux responses in the retinal pigment epithelium to cytokines associated with age-related macular degeneration: comparison of ARPE-19 cells and eyecups.

Distinct metabolome and flux responses in the retinal pigment epithelium to cytokines associated with age-related macular degeneration: comparison of ARPE-19 cells and eyecups.

Journal: Scientific reports
Published: December 05, 2024
Showing 1-12 of 78

Last Updated: 09/26/2026